Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/168743
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

The myeloma stem cell concept, revisited: From phenomenology to operational terms

AutorJohnsen, Hans Erik; Bøgsted, Martin; Schmitz, Alexander; Støve Bødker, Julie; El-Galaly, Tarec Christoffer; Johansen, Preben; Valent, Peter; Zojer, Niklas; Valckenborgh, Els van; Vanderkerken, Karin; Duin, Mark van; Sonneveld, Pieter; Pérez-Andrés, Martin CSIC ORCID CVN; Orfao, Alberto CSIC ORCID ; Dybkær, Karen
Fecha de publicación2016
EditorFerrata Storti Foundation
CitaciónHaematologica 101(12): 1451-1459 (2016)
ResumenThe concept of the myeloma stem cell may have important therapeutic implications, yet its demonstration has been hampered by a lack of consistency in terms and definitions. Here, we summarize the current documentation and propose single-cell in vitro studies for future translational studies. By the classical approach, a CD19–/CD45/CD38/CD138+ malignant plasma cell, but not the CD19/CD38–memory B cell compartment, is enriched for tumorigenic cells that initiate myeloma in xenografted immunodeficient mice, supporting that myeloma stem cells are present in the malignant PC compartment. Using a new approach, analysis of c-DNA libraries from CD19/CD27/CD38–single cells has identified clonotypic memory B cell, suggested to be the cell of origin. This is consistent with multiple myeloma being a multistep hierarchical process before or during clinical presentation. We anticipate that further characterization will require single cell geno-and phenotyping combined with clonogenic assays. To implement such technologies, we propose a revision of the concept of a myeloma stem cell by including operational in vitro assays to describe the cellular components of origin, initiation, maintenance, and evolution of multiple myeloma. These terms are in accordance with recent (2012) consensus statements on the definitions, assays, and nomenclature of cancer stem cells, which is technically precise without completely abolishing established terminology. We expect that this operational model will be useful for future reporting of parameters used to identify and characterize the multiple myeloma stem cells. We strongly recommend that these parameters include validated standard technologies, reproducible assays, and, most importantly, supervised prospective sampling of selected biomaterial which reflects clinical stages, disease spectrum, and therapeutic outcome. This framework is key to the characterization of the cellular architecture of multiple myeloma and its use in precision medicine.
URIhttp://hdl.handle.net/10261/168743
DOI10.3324/haematol.2015.138826
Identificadoresdoi: 10.3324/haematol.2015.138826
e-issn: 1592-8721
issn: 0390-6078
Aparece en las colecciones: (IBMCC) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

35
checked on 23-mar-2024

SCOPUSTM   
Citations

48
checked on 23-mar-2024

WEB OF SCIENCETM
Citations

48
checked on 25-feb-2024

Page view(s)

212
checked on 28-mar-2024

Download(s)

60
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.